Form 8-K - Current report:
SEC Accession No. 0001213900-25-119651
Filing Date
2025-12-09
Accepted
2025-12-09 16:01:03
Documents
14
Period of Report
2025-12-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0269001-8k_pluri.htm   iXBRL 8-K 34652
2 FORM OF WARRANT ea026900101ex4-1_pluri.htm EX-4.1 84580
3 SECURITIES PURCHASE AGREEMENT ea026900101ex10-1_pluri.htm EX-10.1 218259
  Complete submission text file 0001213900-25-119651.txt   580848

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE plur-20251208.xsd EX-101.SCH 3029
5 XBRL LABEL FILE plur-20251208_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE plur-20251208_pre.xml EX-101.PRE 22368
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0269001-8k_pluri_htm.xml XML 3680
Mailing Address MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5 HAIFA Israel
Business Address MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5 HAIFA Israel 972-74-710-7171
Pluri Inc. (Filer) CIK: 0001158780 (see all company filings)

EIN.: 980351734 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-31392 | Film No.: 251558982
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)